Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity

Figure 17 Reported incidences of serious medical conditions from pooled analyses of 5 double-blinded placebo controlled trials studying the safety and efficacy of 3 mg liraglutide (Saxenda) in 3384 overweight or obese subjects receiving liraglutide and 1941 placebo controls. Hypotension associated adverse reactions (Hypo-ADR) refer to hypotension, orthostatic hypotension, circulatory collapse, and decreased blood pressure). One of the six (0.2%) liraglutide treated subjects reporting suicidal ideations attempted suicide. PTC: Papillary thyroid carcinoma; CRC: Colorectal carcinoma; Br Ca: Breast cancer; CCD: Cardiac conduction disorders.